New depression patch put to the skin test
NCT ID NCT07452692
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares a new selegiline skin patch to an existing one (EMSAM®) to see how well the skin tolerates it. Researchers will apply both patches to 230 healthy adults and check for irritation or allergic reactions. The goal is to ensure the new patch is safe for the skin before further testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
selegiline transdermal patch
What this could lead to
If successful, this could confirm that the new selegiline patch is as skin-safe as the existing one, supporting its use for depression treatment.
What could go wrong
This is an early phase 1 trial focused on skin reactions, not on treating depression. It may not predict how well the patch works for depression or cause unexpected skin issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••